VIM-1-producing Pseudomonas mosselii isolates in Italy, predating known VIM-producing index strains.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The spread of carbapenemase-producing bacteria in Africa: a systematic review.The Journal of antimicrobial chemotherapy · 2015
   Pooled it
2. Characterization of antimicrobial resistance and virulence traits of clinicalMicrobiology spectrum · 2026
   Article
3. Difficult-to-treat (DTR)Antimicrobial agents and chemotherapy · 2024
   Article
4. Antibiotic ResistantFoods (Basel, Switzerland) · 2019
   Review
5. Identification of a Novel Plasmid Lineage Associated With the Dissemination of Metallo-β-Lactamase Genes Among Pseudomonads.Frontiers in microbiology · 2019
   Article
6. Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries.BioMed research international · 2014
   Review
7. Cytotoxicity and inflammatory potential of two Pseudomonas mosselii strains isolated from clinical samples of hospitalized patients.BMC microbiology · 2013
   Article
8. Dissemination of a class I integron carrying VIM-2 carbapenemase in Pseudomonas aeruginosa clinical isolates from a hospital intensive care unit in Annaba, Algeria.Antimicrobial agents and chemotherapy · 2013
   Article
9. FIM-1, a new acquired metallo-β-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy.Antimicrobial agents and chemotherapy · 2013
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as